Skip to main content
SpringerLink
Log in

Substance Use Disorders in Pregnancy and Lactation

  • Chapter
  • First Online:
Women's Mood Disorders

  • 1003 Accesses

Abstract

Women use substances and, for some, this use continues during pregnancy. It is not uncommon for women with substance use disorders to have a co-occurring mental health condition. Women who have substance use disorders and/or mental health disorders during and after pregnancy often face tremendous stigma and discrimination that impacts their ability to seek and engage in treatment. When women receive integrated medical and behavioral health care for their substance use and mental health disorders, they and their children have an increased probability of achieving healthy life outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ACOG Committee Opinion No. 757: screening for perinatal depression. Obstet Gynecol. 2018;132(5):e208–12.

    Google Scholar 

  2. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Interventions to prevent perinatal depression: US preventive services task force recommendation statement. JAMA. 2019;321(6):580–7.

    Article  Google Scholar 

  3. Tuten M, Fitzsimons H, Hochheimer M, Jones HE, Chisolm MS. The impact of early substance use disorder treatment response on treatment outcomes among pregnant women with primary opioid use. J Addict Med. 2018;12(4):300–7.

    Article  PubMed  Google Scholar 

  4. American Society of Addiction Medicine. Substance use, misuse, and use disorders during and following pregnancy, with an emphasis on opioids. 2017. https://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2017/01/19/substance-use-misuse-and-use-disorders-during-and-following-pregnancy-with-an-emphasis-on-opioids.

  5. Substance Abuse and Mental Health Services Administration. General principles for the use of pharmacological agents to treat individuals with co-occuring mental and substance use disorders. HHS Publication No. SMA12-4689. Substance Abuse and Mental Health Services Administration: Rockville; 2012.

    Google Scholar 

  6. Lee King PA, Duan L, Amaro H. Clinical needs of in-treatment pregnant women with co-occurring disorders: implications for primary care. Matern Child Health J. 2015;19(1):180–7.

    Article  PubMed  Google Scholar 

  7. Prevatt, BS, Desmarais, SL, Janssen, PA. Lifetime substance use as a predictor of postpartum mental health [Internet]. Arch Womens Ment Health; 2017;20.

    Google Scholar 

  8. Tan CH, Clark HD, Cheal NE, Sniezek JE, Kanny D. Alcohol use and binge drinking among women of childbearing age – United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2015;64(37):1042–6.

    Article  PubMed  Google Scholar 

  9. O’Connor MJ, Whaley SE. Brief intervention for alcohol use by pregnant women. Am J Public Health. 2007;97(2):252–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Carson G, Cox LV, Crane J, Croteau P, Graves L, Kluka S, et al. Alcohol use and pregnancy consensus clinical guidelines. J Obstet Gynaecol Can. 2010;32(8 Suppl 3):S1–31.

    Article  PubMed  Google Scholar 

  11. American College of Obstetricians and Gynecologists. Committee on Health Care for Underserved Women. Committee opinion no. 496: at-risk drinking and alcohol dependence: obstetric and gynecologic implications. Obstet Gynecol. 2011;118(2 Pt 1):383–8.

    Google Scholar 

  12. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH report: substance use among women during pregnancy and following childbirth. SAMHSA: Rockville; 2009. Available at: http://www.oas.samhsa.gov/2k9/135/PregWoSubUse.htm.

    Google Scholar 

  13. Mennella JA, Garcia-Gomez PL. Sleep disturbances after acute exposure to alcohol in mothers’ milk. Alcohol. 2001;25(3):153–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mennella JA, Pepino MY. Biphasic effects of moderate drinking on prolactin during lactation. Alcohol Clin Exp Res. 2008;32(11):1899–908.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Colman GJ, Joyce T. Trends in smoking before, during, and after pregnancy in ten states. Am J Prev Med. 2003;24(1):29–35.

    Article  PubMed  Google Scholar 

  16. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2005. Natl Vital Stat Rep. 2007;56(6):1–103.

    PubMed  Google Scholar 

  17. Tong VT, Jones JR, Dietz PM, D’Angelo D, Bombard JM, Centers for Disease Control and Prevention (CDC). Trends in smoking before, during, and after pregnancy – pregnancy risk assessment monitoring system (PRAMS), United States, 31 sites, 2000-2005. MMWR Surveill Summ. 2009;58(4):1–29.

    PubMed  Google Scholar 

  18. Kuehn B. Vaping and pregnancy. JAMA. 2019;321(14):1344.

    PubMed  Google Scholar 

  19. Spinillo A, Nicola S, Piazzi G, Ghazal K, Colonna L, Baltaro F. Epidemiological correlates of preterm premature rupture of membranes. Int J Gynaecol Obstet. 1994;47(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  20. Castles A, Adams EK, Melvin CL, Kelsch C, Boulton ML. Effects of smoking during pregnancy. Five meta-analyses. Am J Prev Med. 1999;16(3):208–15.

    Article  CAS  PubMed  Google Scholar 

  21. Office of the Surgeon General (US), Office on Smoking and Health (US). The health consequences of smoking: a report of the surgeon general [Internet]. Atlanta: Centers for Disease Control and Prevention (US); 2004 [cited 2020 Aug 28]. (Reports of the Surgeon General). Available from: http://www.ncbi.nlm.nih.gov/books/NBK44695/.

  22. McDonald SD, Walker MC, Ohlsson A, Murphy KE, Beyene J, Perkins SL. The effect of tobacco exposure on maternal and fetal thyroid function. Eur J Obstet Gynecol Reprod Biol. 2008;140(1):38–42.

    Article  CAS  PubMed  Google Scholar 

  23. Dietz PM, England LJ, Shapiro-Mendoza CK, Tong VT, Farr SL, Callaghan WM. Infant morbidity and mortality attributable to prenatal smoking in the U.S. Am J Prev Med. 2010;39(1):45–52.

    Article  PubMed  Google Scholar 

  24. Hurt RD, Renner CC, Patten CA, Ebbert JO, Offord KP, Schroeder DR, et al. Iqmik--a form of smokeless tobacco used by pregnant Alaska natives: nicotine exposure in their neonates. J Matern Fetal Neonatal Med. 2005;17(4):281–9.

    Article  CAS  PubMed  Google Scholar 

  25. Subramoney S, D’espaignet ET, Gupta PC. Higher risk of stillbirth among lower and middle income women who do not use tobacco, but live with smokers. Acta Obstet Gynecol Scand. 2010;89(4):572–7.

    Article  PubMed  Google Scholar 

  26. Søndergaard C, Henriksen TB, Obel C, Wisborg K. Smoking during pregnancy and infantile colic. Pediatrics. 2001;108(2):342–6.

    Article  PubMed  Google Scholar 

  27. von Kries R, Toschke AM, Koletzko B, Slikker W. Maternal smoking during pregnancy and childhood obesity. Am J Epidemiol. 2002;156(10):954–61.

    Article  Google Scholar 

  28. Li Y-F, Langholz B, Salam MT, Gilliland FD. Maternal and grandmaternal smoking patterns are associated with early childhood asthma. Chest. 2005;127(4):1232–41.

    PubMed  Google Scholar 

  29. Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health. 2008;85(6):858–73.

    Article  PubMed  PubMed Central  Google Scholar 

  30. El Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Verhulst FC, van den Brink W, et al. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study. Eur Addict Res. 2011;17(1):37–43.

    Article  PubMed  Google Scholar 

  31. van Gelder MMHJ, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N, et al. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend. 2010;109(1–3):243–7.

    Article  PubMed  Google Scholar 

  32. Beatty JR, Svikis DS, Ondersma SJ. Prevalence and perceived financial costs of marijuana versus tobacco use among urban low-income pregnant women. J Addict Res Ther [Internet]. 2012 [cited 2020 Aug 28];3(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709859/.

  33. Passey ME, Sanson-Fisher RW, D’Este CA, Stirling JM. Tobacco, alcohol and cannabis use during pregnancy: clustering of risks. Drug Alcohol Depend. 2014;134:44–50.

    Article  PubMed  Google Scholar 

  34. Moore DG, Turner JD, Parrott AC, Goodwin JE, Fulton SE, Min MO, Fox HC, Braddick FM, Axelsson EL, Lynch S, Ribeiro H, Frostick CJ, Singer LT. During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study [Internet]. J Psychopharmacol (Oxford, England). 2010 [cited 2020 Sep 16];24. Available from: https://pubmed.ncbi.nlm.nih.gov/19939863/.

  35. Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M. Pregnant women’s current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–6.

    Article  PubMed  Google Scholar 

  36. Ostrea EM, Ostrea AR, Simpson PM. Mortality within the first 2 years in infants exposed to cocaine, opiate, or cannabinoid during gestation. Pediatrics. 1997;100(1):79–83.

    Article  PubMed  Google Scholar 

  37. Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. BJOG Int J Obstet Gynaecol. 2002;109(1):21–7.

    Article  Google Scholar 

  38. Warshak CR, Regan J, Moore B, Magner K, Kritzer S, Van Hook J. Association between marijuana use and adverse obstetrical and neonatal outcomes. J Perinatol. 2015;35(12):991–5.

    Article  CAS  PubMed  Google Scholar 

  39. Committee Opinion No. 722: Marijuana use during pregnancy and lactation [Internet]. Obstet Gynecol. 2017;130. Available from: https://pubmed.ncbi.nlm.nih.gov/28937574/.

  40. Chandler LS, Richardson GA, Gallagher JD, Day NL. Prenatal exposure to alcohol and marijuana: effects on motor development of preschool children. Alcohol Clin Exp Res. 1996;20(3):455–61.

    Article  CAS  PubMed  Google Scholar 

  41. Fried, PA, Watkinson, B. Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana [Internet]. Neurotoxicol Teratol. 2001 [cited 2020 Sep 16];23. Available from: https://pubmed.ncbi.nlm.nih.gov/11711244/.

  42. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana [Internet]. Neurotoxicol Teratol. 2003 [cited 2020 Sep 16]; 25. Available from: https://pubmed.ncbi.nlm.nih.gov/12798960/.

  43. Day, NL, Goldschmidt, L, Thomas, CA. Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14 [Internet]. Addiction (Abingdon, England). 2006 [cited 2020 Sep 16];101. Available from: https://pubmed.ncbi.nlm.nih.gov/16911731/.

  44. Linn S, Schoenbaum SC, Monson RR, Rosner R, Stubblefield PC, Ryan KJ. The association of marijuana use with outcome of pregnancy. Am J Public Health. 1983;73(10):1161–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol. 2004;26(4):521–32.

    Article  CAS  PubMed  Google Scholar 

  46. Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med. 2015;10(3):135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Haight SC. Opioid Use Disorder Documented at Delivery Hospitalization — United States, 1999–2014. MMWR Morb Mortal Wkly Rep [Internet]. 2018 [cited 2020 Aug 28];67. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6731a1.htm.

  48. Martin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abus Treat. 2015;48(1):37–42.

    Article  Google Scholar 

  49. Hand DJ, Short VL, Abatemarco DJ. Substance use, treatment, and demographic characteristics of pregnant women entering treatment for opioid use disorder differ by United States census region. J Subst Abus Treat. 2017;76:58–63.

    Article  Google Scholar 

  50. Center for substance abuse treatment. Medication-assisted treatment for opioid addiction during pregnancy. Rockville; 2005.

    Google Scholar 

  51. Patrick SW, Davis MM, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009-2012. J Perinatol. 2015;35(8):650–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Committee on Obstetric Practice. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81–94.

    Article  Google Scholar 

  53. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. [Internet]. Rockville: Substance Abuse and Mental Health Services Administration; 2018 [cited 2020 Aug 28]. Available from: https://www.drugsandalcohol.ie/28957/.

  54. Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65(8):839–46.

    Article  CAS  PubMed  Google Scholar 

  55. Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med. 2010;13(3):235.

    Article  PubMed  Google Scholar 

  56. Riska BS, Skurtveit S, Furu K, Engeland A, Handal M. Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based cohort study. Eur J Clin Pharmacol. 2014;70(11):1367–74.

    Article  CAS  PubMed  Google Scholar 

  57. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth. 2014;14:242.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136–42.

    Article  Google Scholar 

  59. Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng H. Association of maternal use of benzodiazepines and Z-hypnotics during pregnancy with motor and communication skills and attention-deficit/hyperactivity disorder symptoms in preschoolers. JAMA Netw Open. 2019;2(4):e191435.

    Article  PubMed  PubMed Central  Google Scholar 

  60. National Collaborating Centre for Mental Health (UK). Antenatal and postnatal mental health: clinical management and service guidance: updated edition [Internet]. Leicester: British Psychological Society; 2014 [cited 2020 Aug 28]. (National Institute for Health and Clinical Excellence: Guidance). Available from: http://www.ncbi.nlm.nih.gov/books/NBK305023/.

  61. Wikner BN, Stiller C-O, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203–10.

    Article  PubMed  Google Scholar 

  62. Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB, editors. The American psychiatric publishing textbook of psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing, Inc.; 2009. p. 1323–412.

    Google Scholar 

  63. Plessinger MA, Woods JR. Maternal, placental, and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol. 1993;36(2):267–78.

    Article  CAS  PubMed  Google Scholar 

  64. Bandstra ES, Vogel AL, Morrow CE, Xue L, Anthony JC. Severity of prenatal cocaine exposure and child language functioning through age seven years: a longitudinal latent growth curve analysis. Subst Use Misuse. 2004;39(1):25–59.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Gouin K, Murphy K, Shah PS. Knowledge synthesis group on determinants of low birth weight and preterm births. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204(4):340.e1–12.

    Article  CAS  Google Scholar 

  66. Jones HE, O’Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17(5):372–86.

    Article  PubMed  Google Scholar 

  67. Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr. 2010;157(2):337–9.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Arria AM, Derauf C, Lagasse LL, Grant P, Shah R, Smith L, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the infant development, environment, and lifestyle (IDEAL) study. Matern Child Health J. 2006;10(3):293–302.

    Article  PubMed  Google Scholar 

  69. Gorman MC, Orme KS, Nguyen NT, Kent EJ, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211(4):429.e1–7.

    Article  CAS  Google Scholar 

  70. Bose J. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. 2017;124.

    Google Scholar 

  71. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2008;112(6):1449–60.

    Article  Google Scholar 

  72. American College of Obstetrics and Gynecology Committee on Ethics. ACOG Committee Opinion No 633: alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2015;125(6):1529–37.

    Article  Google Scholar 

  73. Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019;221(1):B5–28.

    Article  PubMed  Google Scholar 

  74. DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015;23(2):112–21.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Ondersma SJ, Chang G, Blake-Lamb T, Gilstad-Hayden K, Orav J, Beatty JR, et al. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019;114(9):1683–93.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Kendig S, Keats JP, Hoffman MC, Kay LB, Miller ES, Moore Simas TA, Frieder A, Hackley B, Indman P, Raines C, Semenuk K, Wisner KL, Lemieux LA. Consensus bundle on maternal mental health: perinatal depression and anxiety. Obstet Gynecol. 2017;129. Available from: https://pubmed.ncbi.nlm.nih.gov/28178041/.

  77. Krans EE, Campopiano M, Cleveland LM, et al. National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder. Obstet Gynecol. 2019;134(2):365–75. https://doi.org/10.1097/AOG.0000000000003381.

    Article  PubMed  Google Scholar 

  78. American Psychiatric Association. Diagnostic and statistical manual (DSM-V). Washington, DC: American Psychiatric Association; 2013.

    Google Scholar 

  79. Substance Abuse and Mental Health Services Administration. Substance use disorder treatment for people with co-occurring disorders. Treatment improvement protocol (TIP) series, No. 42. SAMHSA publication No. PEP20-02-01-004. Substance Abuse and Mental Health Services Administration: Rockville; 2020.

    Google Scholar 

  80. Guidelines for the identification and management of substance use and substance use disorders in pregnancy [Internet]. Geneva: World Health Organization; 2014 [cited 2020 Aug 28]. (WHO Guidelines Approved by the Guidelines Review Committee). Available from: http://www.ncbi.nlm.nih.gov/books/NBK200701/.

  81. Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, et al. Opioid detoxification during pregnancy. Obstet Gynecol. 2018;131(5):803–14.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Gopman S. Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin N Am. 2014;41(2):213–28.

    Article  Google Scholar 

  83. Peng PWH, Tumber PS, Gourlay D. Review article: perioperative pain management of patients on methadone therapy. Can J Anesth. 2005;52(5):513–23.

    Article  PubMed  Google Scholar 

  84. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Salisbury AL, Coyle MG, O’Grady KE, Heil SH, Martin PR, Stine SM, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction. 2012;107(01):36–44.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Komatsu R, Carvalho B, Flood PD. Recovery after nulliparous birth: a detailed analysis of pain analgesia and recovery of function. Anesthesiology. 2017;127(4):684–94.

    Article  PubMed  Google Scholar 

  87. Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, Huybrechts KF, et al. Patterns of opioid prescription and use after cesarean delivery. Obstet Gynecol. 2017;130(1):29–35.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Wong CA, Girard T. Undertreated or overtreated? Opioids for postdelivery analgesia. Br J Anaesth. 2018;121(2):339–42.

    Article  CAS  PubMed  Google Scholar 

  89. Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132(2):466–74.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Holbrook A, Kaltenbach K. Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression. Am J Drug Alcohol Abuse. 2012;38(6):575–9.

    Article  PubMed  Google Scholar 

  91. Chapman SLC, Wu L-T. Postpartum substance use and depressive symptoms: a review. Women Health. 2013;53(5):479–503.

    Article  PubMed  PubMed Central  Google Scholar 

  92. WHO | Contraception [Internet]. WHO. World Health Organization; [cited 2020 Aug 28]. Available from: http://www.who.int/reproductivehealth/publications/contraception-evidence-brief/en/.

  93. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6):e1163–9.

    Article  PubMed  Google Scholar 

  94. Jansson LM. Neonatal abstinence syndrome. Acta Paediatr. 2008;97(10):1321–3.

    Article  PubMed  Google Scholar 

  95. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. Addict Sci Clin Pract. 2014;9(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Jones HE, Seashore C, Johnson E, Horton E, O’Grady KE, Andringa K, et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS scale. Am J Addict. 2016;25(5):370–3.

    Article  PubMed  Google Scholar 

  97. Patrick SW, Schumacher RE, Horbar JD, Buus-Frank ME, Edwards EM, Morrow KA, et al. Improving care for neonatal abstinence syndrome. Pediatrics. 2016;137(5).

    Google Scholar 

  98. Atwood EC, Sollender G, Hsu E, Arsnow C, Flanagan V, Celenza J, et al. A qualitative study of family experience with hospitalization for neonatal abstinence syndrome. Hosp Pediatr. 2016;6(10):626–32.

    Article  PubMed  Google Scholar 

  99. Holmes AV, Atwood EC, Whalen B, Beliveau J, Jarvis JD, Matulis JC, et al. Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost. Pediatrics. 2016;137(6).

    Google Scholar 

  100. MacMillan KDL, Rendon CP, Verma K, Riblet N, Washer DB, Volpe HA. Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatr. 2018;172(4):345–51.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counseling to postdischarge follow-up care: results of a national survey. Hosp Pediatr. 2013;3(4):317–23.

    Article  PubMed  Google Scholar 

  102. Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8(1):1–6.

    Article  PubMed  Google Scholar 

  103. Wachman EM, Grossman M, Schiff DM, Philipp BL, Minear S, Hutton E, et al. Quality improvement initiative to improve inpatient outcomes for neonatal abstinence syndrome. J Perinatol. 2018;38(8):1114–22.

    Article  PubMed  Google Scholar 

  104. Blount T, Painter A, Freeman E, Grossman M, Sutton AG. Reduction in length of stay and morphine use for NAS with the “eat, sleep, console” method. Hosp Pediatr. 2019;9(8):615–23.

    Article  PubMed  Google Scholar 

  105. Covington SS. Women and addiction: a trauma-informed approach. J Psychoactive Drugs. 2008;Suppl 5:377–85.

    Article  PubMed  Google Scholar 

  106. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070–6. https://doi.org/10.1097/AOG.0b013e318256496e.

    Article  Google Scholar 

  107. Catalyst N. What is patient-centered care? NEJM Catalyst [Internet]. 2017 [cited 2020 Sep 1]; Available from: https://catalyst.nejm.org/doi/abs/10.1056/CAT.17.0559.

  108. Meyer M, Benvenuto A, Howard D, Johnston A, Plante D, Metayer J, Mandell T. Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome. J Addict Med. 2012;6(2):124–30. https://doi.org/10.1097/ADM.0b013e3182541933.

    Article  PubMed  Google Scholar 

  109. Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard [published correction appears in J Perinatol. 2009 Feb;29(2):181]. J Perinatol. 2008;28(9):597–603. https://doi.org/10.1038/jp.2008.70.

    Article  CAS  PubMed  Google Scholar 

  110. Goodman D. Improving access to maternity care for women with opioid use disorders: colocation of midwifery services at an addiction treatment program. J Midwifery Womens Health. 2015;60(6):706–12.

    Article  PubMed  Google Scholar 

  111. Brogly SB, Saia KE, Werler MM, Regan E, Hernandez-Diaz S. Prenatal treatment and outcomes of women with opioid use disorder. Obstet Gynecol. 2018;132(4):916–22.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UNC Horizons, Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Elisabeth Johnson

  2. Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Susan Myers

Authors
  1. Elisabeth Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth Johnson .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Elizabeth Cox

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Johnson, E., Myers, S. (2021). Substance Use Disorders in Pregnancy and Lactation. In: Cox, E. (eds) Women's Mood Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-71497-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71497-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71496-3

  • Online ISBN: 978-3-030-71497-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation